Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News Nanobiotix ADR Representing Ord Shs NBTX

Healthcare Biotechnology
Nanobiotix SA is a France-based nanomedicine company. The Company designs and manufactures nanoparticles that safely enhance the efficacy of radiation therapy in the treatment of cancer. It develops new tools for cancer that utilize a physical mode of action at the cellular level of the cancer cell. The Company's NanoXray technology comprises three products. Local treatment (surgery and... see more

Recent & Breaking News (NDAQ:NBTX)

NANOBIOTIX: Statement of Total Voting Rights and Shares Forming the Company's Share Capital

Business Wire June 9, 2022

NANOBIOTIX: New Data Featuring NBTXR3 Plus Chemoradiation and in the Preoperative Setting Support Broad Applicability for Head and Neck Cancer and Other Solid Tumor Indications

Business Wire June 5, 2022

NANOBIOTIX Annual Shareholders' General Meeting to Be Held on June 23, 2022

Business Wire June 2, 2022

CORRECTING and REPLACING: NANOBIOTIX Provides First Quarter Operational and Financial Update

Business Wire May 18, 2022

NANOBIOTIX Provides First Quarter Operational and Financial Update

Business Wire May 18, 2022

NANOBIOTIX to Present During the Jefferies Healthcare Conference in June 2022

Business Wire May 17, 2022

NANOBIOTIX to Participate in Two Upcoming Investor Conferences

Business Wire May 11, 2022

Nanobiotix: Statement of Total Voting Rights and Shares Forming the Company's Share Capital

Business Wire May 10, 2022

NANOBIOTIX to Announce First Quarter 2022 Financial Results on May 18, 2022

Business Wire May 4, 2022

New Data Featuring NANOBIOTIX Lead Product Candidate NBTXR3 to Be Presented at the 2022 ASCO Annual Meeting

Business Wire May 2, 2022

NANOBOTIX: New Preclinical Immunotherapy Data Show Boosted Anti-Tumor Immune Activation via Triple Blockade of PD-1, LAG-3, and TIGIT When Combined With Radiotherapy-Activated NBTXR3

Business Wire April 11, 2022

NANOBIOTIX Announces Filing of the 2021 Universal Registration Document and the 2021 Annual Report on Form 20-F

Business Wire April 8, 2022

Nanobiotix: Statement of Total Voting Rights and Shares Forming the Company's Share Capital

Business Wire April 7, 2022

 NANOBIOTIX Provides Business Update and Reports Full Year 2021 Financial Results

Business Wire March 30, 2022

NANOBIOTIX to Announce Full Year 2021 Financial Results on March 30, 2022

Business Wire March 16, 2022

Nanobiotix: Statement of Total Voting Rights and Shares Forming the Company's Share Capital

Business Wire March 8, 2022

Nanobiotix: Statement of Total Voting Rights and Shares Forming the Company's Share Capital

Business Wire February 10, 2022

Nanobiotix Announces Publication of New Clinical Case Study Highlighting First Patient Experience of NBTXR3 Treatment for Pancreatic Cancer

Business Wire February 9, 2022

NANOBIOTIX Announces Publication of New Preclinical Immunotherapy Data Showcasing the Combination Potential of NBTXR3 With anti-PD-1 and anti-CTLA-4

Business Wire January 26, 2022

Nanobiotix: Statement of Total Voting Rights and Shares Forming the Company's Share Capital

Business Wire January 11, 2022